Item 5. Market for Registrant’s Common Equity
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Our common stock began trading on the Nasdaq Global Select Market on July 23, 2021 and trades under the symbol “CTKB”. Prior to July 23, 2021, there was no public trading market for our common stock.
Holders of Record
As of February 17, 2026 , there were 15 stockholders of record. Because brokers and other institutions hold many of our shares on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders.
Dividend Policy
We have never declared or paid any cash dividends on our capital stock and we do not currently intend to pay any cash dividends on our capital stock for the foreseeable future. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. Any future determination to pay dividends will be made at the discretion of our board of directors, subject to applicable laws and will depend upon, among other factors, our results of operations, financial condition, contractual restrictions and capital requirements.
Recent Sales of Unregistered Equity Securities
None.
Use of Proceeds
In July 2021, we issued and sold an aggregate of 13,949,401 shares of common stock in connection with our initial public offering (“IPO”), including the full exercise by the underwriters of their option to purchase an additional 2,184,695 shares from us, and the selling stockholders sold 2,799,929 shares of common stock, at a public offering price of $17.00 per share. All of the shares of common stock issued and sold in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1 (Registration No. 333-257663), which was declared effective by the SEC on July 22, 2021. There has been no material change in the use of proceeds from our IPO from those disclosed in the final prospectus for our IPO dated July 22, 2021 and filed with the SEC pursuant to Rule 424(b)(4) of the Securities Act on July 23, 2021.
Issuer Purchases of Equity Securities
On June 5, 2024, our board of directors approved a program for the repurchase of up to an aggregate of $50 million of our outstanding common stock, which expired on December 31, 2024. On December 11, 2024, the Board approved a new program for the repurchase by the Company of up to an aggregate of $50 million of its outstanding common stock commencing January 1, 2025, which expired on December 31, 2025. As of December 31, 2025, the Company had a remaining authorized amount of $35.0 million in the repurchase program. The repurchase programs were used to return capital to shareholders and to minimize the dilutive impact of stock options and other stock-based awards. The repurchased shares of common stock were retired.
The following table provides information with respect to the repurchase of shares of our common stock from the commencement of the repurchase program until its expiration on December 31, 2025.
69
Table of Contents
(Except for the share amount and average price per share, dollar value in thousands)
Total number of shares repurchased Average price paid per share ($)
Total number of shares purchased as part of publicly announced plans or programs Approximate dollar value of shares that may yet be purchased under the plans or programs ($)
Beginning Balance - December 31, 2024 10,585,404 $ 6.19 10,585,404 $ 28,500,000
January 1 – January 31, 2025 607,522 5.76 11,192,926 46,500,007
February 1 – February 28, 2025 658,878 5.31 11,851,804 43,000,014
March 1 – March 31, 2025 812,183 4.31 12,663,987 39,500,021
April 1 – April 30, 2025 939,946 3.72 13,603,933 36,000,023
May 1 – May 31, 2025 274,059 3.65 13,877,992 35,000,023
Jun 1 - December 31, 2025 — — — —
Life to Date Total* 13,877,992 $ 5.80 13,877,992 $ 35,000,023
* The share repurchase program expired on December 31, 2025.
The commission costs related to the repurchases were $— million and $0.07 million for the three months and twelve months ended December 31, 2025, respectively.
On August 16, 2022, the Inflation Reduction Act of 2022 (the “IRA”), was signed into law. Among other things, the IRA imposes a 15% corporate alternative minimum tax for tax years beginning after December 31, 2022, levies a 1% excise tax on net stock repurchases after December 31, 2022, and provides tax incentives to promote clean energy. Beginning in 2023, net stock repurchases are subject to the excise tax. As of December 31, 2025, we have accrued $0.1 million excise taxes related with our shares repurchases.
Stock Performance Graph
This Section is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by reference in any filing of Cytek Biosciences under the Securities Act of 1933, as amended (the “Securities Act”), or the Securities Exchange Act of 1934, as amended (the “Exchange Act”), whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.
70
Table of Contents
The following graph compares the cumulative total return on an investment of $100 in cash on July 23, 2021 through December 31, 2025 , in our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Components Index and assuming that all dividends were reinvested. The stockholder return shown on the graph below is based on historical data and is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.
Item 6. [Reserved]
71
Table of Contents